Mizuho Issues Pessimistic Forecast for LivaNova (NASDAQ:LIVN) Stock Price

LivaNova (NASDAQ:LIVN - Free Report) had its price objective cut by Mizuho from $70.00 to $60.00 in a report released on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

LIVN has been the subject of several other reports. Stifel Nicolaus reduced their price objective on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday. Wolfe Research downgraded LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday. StockNews.com upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 14th. Robert W. Baird upped their target price on LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Finally, Needham & Company LLC cut their target price on LivaNova from $75.00 to $64.00 and set a "buy" rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $64.20.

Remove Ads

LivaNova Stock Performance

Shares of NASDAQ LIVN traded up $0.70 during midday trading on Wednesday, hitting $41.63. 807,916 shares of the company's stock were exchanged, compared to its average volume of 582,675. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The stock's 50 day moving average price is $47.40 and its 200-day moving average price is $49.53. The firm has a market cap of $2.26 billion, a P/E ratio of 99.12 and a beta of 1.00. LivaNova has a twelve month low of $40.37 and a twelve month high of $64.47.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the company's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now owns 7,522 shares of the company's stock, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.27% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of LivaNova by 12.7% in the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after buying an additional 265,291 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock valued at $109,914,000 after buying an additional 806,374 shares in the last quarter. Capital Research Global Investors increased its holdings in shares of LivaNova by 19.1% in the fourth quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock valued at $74,690,000 after buying an additional 258,730 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of LivaNova by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock valued at $70,676,000 after buying an additional 8,331 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of LivaNova by 8.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company's stock valued at $60,710,000 after buying an additional 107,693 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.